Catheter Precision, Inc. announced on June 30, 2025, the formation of a new joint venture named Kardionav. This venture is a joint development company between VTAK and physicians.
Kardionav is established to pursue the latest in technology surrounding the area of ablation for ventricular tachycardia (VT). The venture aims to exploit patented AI techniques to create a new VT software platform.
This strategic initiative is designed to add new applications to cardiac ventricular therapies and further enhance the VIVO technology intellectual property portfolio. The focus on AI techniques represents an advancement in the company's approach to cardiac electrophysiology solutions.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.